FOXM1 contributes to treatment failure in acute myeloid leukemia

Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. Our previous work has shown that these favorable outcomes are linked to the cytoplasmic relocalization and inactivation of FOXM1 driven by mutated NPM1. Here, we went on to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Irum, Halasi, Marianna, Patel, Anand, Schultz, Rachael, Kalakota, Nandini, Chen, Yi-Hua, Aardsma, Nathan, Liu, Li, Crispino, John D., Mahmud, Nadim, Frankfurt, Olga, Gartel, Andrei L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129129/
https://www.ncbi.nlm.nih.gov/pubmed/30089730
http://dx.doi.org/10.1172/jci.insight.121583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129129/
https://www.ncbi.nlm.nih.gov/pubmed/30089730
http://dx.doi.org/10.1172/jci.insight.121583

Ejemplares similares